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Abstract In omics research often high-dimensional data
is collected according to an experimental design. Typically,
the manipulations involved yield differential effects on
subsets of variables. An effective approach to identify
those effects is ANOVA-simultaneous component analysis
(ASCA), which combines analysis of variance with prin-
cipal component analysis. So far, pre-treatment in ASCA
received hardly any attention, whereas its effects can be
huge. In this paper, we describe various strategies for
scaling, and identify a rational approach. We present the
approaches in matrix algebra terms and illustrate them with
an insightful simulated example. We show that scaling
directly influences which data aspects are stressed in the
analysis, and hence become apparent in the solution.
Therefore, the cornerstone for proper scaling is to use a
scaling factor that is free from the effect of interest. This
implies that proper scaling depends on the effect(s) of in-
terest, and that different types of scaling may be proper for
the different effect matrices. We illustrate that different
scaling approaches can greatly affect the ASCA interpre-
tation with a real-life example from nutritional research.
The principle that scaling factors should be free from the
effect of interest generalizes to other statistical methods
that involve scaling, as classification methods.
Keywords Pre-treatment  Designed experiments 
High-dimensional data
1 Introduction
In metabolomics, transcriptomics, proteomics and next
generation sequencing (NGS), experimental data are ob-
tained on the abundance of (very) large numbers of bio-
molecules in biological material. Typically, the
manipulations involved yield differential effects on subsets
of such biomolecules since they are often obtained under
different conditions (treatment, time,…). In the absence of
specific theoretical guidance, the key challenge is to un-
ravel the nature of the differential effects and the associ-
ated subsets of biomolecules on the basis of the empirical
data. We will focus on metabolomics, but the methods
described also translate to other (omics) data.
A classical and powerful tool to identify such subsets is
principal component analysis (PCA). PCA reveals domi-
nant sources of variance in the observed data. However,
straightforward use of PCA is typically not effective in this
setting, because the thus identified dominant sources will
not necessarily be linked to the experimental manipula-
tions. In particular the between-subject variability within
experimental conditions is often large (Xu et al. 2014),
implying that the effects of the manipulations remain
hidden in PCA results.
An effective exploratory alternative that accounts for the
experimental design, and hence explicitly identifies and
disentangles sources of variation due to the experimental
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manipulations, is ANOVA-simultaneous component ana-
lysis (ASCA) (Jansen et al. 2005; Smilde et al. 2005). The
core idea of ASCA is to decompose the observed data
matrix into a series of additive effect matrices, according to
the experimental design, and subsequently perform a PCA
on the effect matrices of interest. The latter is done to
identify the dominant sources of variation for that par-
ticular effect. The ASCA approach has been fruitfully ap-
plied in a range of application areas (de Noord and
Theobald 2005; Ferreira et al. 2009; Xu et al. 2014).
Although ASCA sheds light on different sources of
variation, its results may still heavily depend on differences
in variances of the metabolites within each of the effect
matrices and thus depend on the pre-treatment applied to
data. Pre-treatment is standard practice in metabolomics in
order to focus on the biologically relevant information
(Goodacre et al. 2007; van den Berg et al. 2006).
The pre-treatment steps in ASCA are the same ones as in
PCA: centering, typically around the mean, and scaling.
Scaling pertains to dividing each variable by a factor, for
example the variable’s standard deviation. The possibly
large effects of the specific pre-treatment applied are well-
known in the context of PCA (e.g., Vandenginste et al.
1998) but received hardly any attention in ASCA so far.
This lack of attention is understandable for centering, be-
cause this type of pre-treatment is implicitly dealt with in
ASCA via the additive effect matrices, which are centered
around the mean. In contrast, scaling is an important issue
in ASCA. The possible effects on the analysis results are as
large as in PCA, while the number of possible scaling
strategies is much larger.
So far, in empirical applications, ASCA is pre-
dominantly applied to unscaled data (Jansen et al. 2005;
Lemanska et al. 2012; Mazerolles et al. 2011; e.g., Smilde
et al. 2005; Wang et al. 2009) and only incidentally to
autoscaled data [i.e., each variable with length one across
all observations (e.g., Ferreira et al. 2009)], or effect scaled
data [i.e., separately scaled effect matrices (e.g., van Vel-
zen et al., 2008)]. However, a rationale for the scaling
applied is consistently lacking. This is a pity, since it
hampers judging whether the solution interpreted optimally
reflects the phenomena of interest.
In this paper, we aim at offering insight in which scaling
strategies are rational in ASCA. We will show that scaling
directly influences which data aspects are stressed in the
analysis, and hence become apparent in the solution. We
will argue that a proper scaling depends on which effects
are of interest, and hence that different types of scaling
may be proper for the different effect matrices. In the ab-
sence of an external objective criterion for judging the
adequacy of the scaling strategies, we base our discussion
of these strategies on theoretical justification and their
impact on the solution.
We start by explaining, in mathematical terms, the
ASCA model, its estimation, the effects of scaling on the
solution and different scaling variants. For ease of expla-
nation, we do so on the basis of a small experimental de-
sign that shows the basic principles relevant for scaling.
The thus shown principles are generalizable to any, more
complicated, experimental design. Next, we use a toy ex-
ample to show the effects of various types of scaling on
different effect matrices with a small simulated data set.
Then, we analyze a real-life metabolomics data set. We end
by discussing the implications when applying ASCA and
related methods to scaled data in practice.
2 Theory: ASCA model and scaling
2.1 Model and estimation
For ease of explanation, we consider a small example: a
nested balanced experimental design, with a between-
subject factor ‘treatment’ and a within-subject factor
‘time’. There are J treatments (j = 1,…,J), with Ij =
I subjects (ij = 1,…,I) in treatment j. This yields N = JI
subjects in total. Each subject is measured at K comparable
time points (k = 1,…,K), implying that the scores at time
point k can be sensibly compared across subjects (Van
Mechelen and Smilde 2011). At each time point k for all
N subjects, L dependent variables (e.g., metabolites)
(l = 1,…,L) are measured. The observed scores can be
collected in a data matrix X (NK 9 L).
The ANOVA model for a single metabolite l, can be
formulated as (cf. Winer 1971)
xjkij ¼ lþ aj þ bk þ abð Þjkþejkij ; ð1Þ
where l indicates an overall offset, aj the effect of ‘treat-
ment’, bk the effect of ‘time’, (ab)kj the interaction of
‘treatment’ and ‘time’, and ejkij the subject specific de-
viation. In ASCA, the data matrix X (NK 9 L) is first de-
composed into a few effect matrices according to the model
in Eq. (1), as:
X ¼ 1mT þ Xa þ Xb þ Xab þ XE ð2Þ
where 1 (NK 9 1) consists of ones, mT (1 9 L) contains
the means of the L variables computed across all NK ob-
servations; Xa and Xb hold the level means for the factors
‘treatment’ and ‘time’, respectively; Xab the interaction
terms for those two factors; and XE the subject-specific
effects. The latter express the variation between subjects at
each time point within each treatment. Note that the effect
matrices are highly structured: all rows related to one level
of the factor in question are equal (e.g., all rows of Xa
pertaining to treatment j). Further, all effect matrices have
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b;k ¼ 0T, etc., where
xa,j
T indicate the rows of effect matrix Xa pertaining to
treatment j).
To identify the dominant sources of variation for the
effects of interest, PCA is applied to the associated effect
matrices or to an additive combination thereof. We con-
sider two different types of effects that are of interest in
practice, the between and within effects. Note that in most
applications of ASCA only the between effect is consid-
ered, but, for example, Xu et al. (2014) study both.
The between effect expresses the main effect of treat-
ment and its differential effects across time, and is modeled
through a PCA of (Xa 1 Xab) = X(a?ab).
The within effect pertains to the natural variation across
individuals at each time point within each condition, and is
analyzed via a PCA of XE. Herewith, one focuses on
identifying variables with relatively large and similar
residual patterns across time points and treatments. This
may reveal important information on possible differential
effects of a particular treatment condition across indi-
viduals. The size, onset and nature of treatment effects may
substantially differ across individuals, even when they
would be sampled from a (seemingly) single population.
This opens the possibility of subtyping and understanding
personalized treatment effects.
To understand the effects of scaling it is important to
know that the separate PCA’s on the effect matrices are
equivalent to the minimization of a specific least-squares
estimation problem in terms of the observed data matrix
X. For the model described above, the associated ordinary
least-squares (OLS) loss function boils down to
where T(.) (NK 9 Q(.)) and P(.) (L 9 Q(.)) denote the
component score matrix and loading matrix, respectively,
for effect (.), with (a ? ab) the between effect and (E) the
within effect; and subject to the sum constraint of zero for
each effect matrix and each component score matrix (for
details, see the Supplementary Material (SM)).
The fits of the different parts of an ASCA model are
typically expressed as a percentage of variance explained
(VAF). For the ANOVA part, we consider for each effect
matrix the VAF of the total data (yielding the between-
VAF and within-VAF). For the PCA parts, we consider for
each component the VAF of its effect matrix. Regarding
the number of components, we consider, in line with pre-
vious applications, maximally two components per effect
matrix, retaining those components with a proper sub-
stantive interpretation. No formal criterion is available to
indicate the number of components Q(.) needed to
adequately describe the between and within effects. Such a
criterion could be based on principles used in other forms
of component analysis (e.g., CHull (Ceulemans and Kiers
2006) or Parallel analysis (Horn 1965)), but their use in
ASCA context is not straightforward.
In the ASCA model, the mean at each time point is ex-
plicitly modelled. This is possible because all subjects are
measured at the very same time points. Explicit modeling of
themean is denoted as the fixed effects approach tomodeling
longitudinal data (Snijders and Bosker 1999). A more so-
phisticated alternative would be to model the repeated
measures as if they are observations on a population of
curves. Then, one could also model data collected at time
points that vary across subjects and one would take the full
advantage of any functional relationship between the time
points. However, as combining such an approach with PCA
is far from straightforward, this is topic of further research.
2.2 Scaling in ASCA: weighting different parts
Scaling is defined as dividing each variable by a certain
factor before subsequent analysis. Different scaling factors
have been proposed, serving different goals, and with as-
sociated merits and drawbacks. For an overview we refer to
van den Berg et al. (2006). Here, we consider the standard
deviation, as a measure of data dispersion. Note, however,
that the discussed consequences of scaling generalize to
any other scaling factor considered.
Suppose that a scaled version ~X of the input data matrix
X would be analyzed with ASCA. Specifically, assume that
the data matrix was scaled by dividing each variable l by
the corresponding standard deviation sl, l = 1,…,L, across
all rows. This implies that ~X ¼ XW with ~X the scaled
matrix, X the input data and W a diagonal weight matrix
(L 9 L), with the inverse of the standard deviations sl,
l = 1,…,L, on its diagonal. The consequences of this
ð3Þ
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scaling for the estimated component score and loading
matrices become clear by considering the OLS loss func-
tion (3), in terms of ~X ¼ XW. As shown in the context of
PCA and three-way component analysis, an OLS analysis
of thus scaled data is equivalent to a weighted least squares
(WLS) analysis of the input data (Bro and Smilde 2003;
Harshman and Lundy 1984). For ASCA, starting from
Eq. (3), this can be seen as follows:
with ~mT ¼ mTW, ~Xb ¼ XbW, ~X aþabð Þ ¼ X aþabð ÞW aþabð Þ,
~XE ¼ XEWE, ~P aþabð Þ ¼ P aþabð ÞW aþabð Þ, ~PE ¼ PEWE, and
W aþabð Þ ¼ WE ¼ W. Thus, ASCA on the scaled matrix
(i.e., ~X ¼ XW) is equivalent to ASCA on the input data
matrix (i.e., X) using a WLS loss function with weight
matrix W. Note that this equivalence does hold because the
weights are column specific (as, e.g., in autoscaling), and
would not hold when the weights would be element
specific (as in the general WLS definition, using the
Hadamard product).
From Eq. (4), it follows that scaling boils down to dif-
ferently weighting the variables when computing the so-
lution and thus implies a change in the objective function,
except for the trivial case of W = cI, with c an arbitrary
constant. The ASCA solutions based on unscaled and
scaled data will generally differ more with increasing
variability in the diagonal elements of W. Generally,
variables with relative large weights in W contribute to a
larger extent to the loss value, and hence will influence the
solution to a larger extent than in the unscaled analysis. In
the unscaled data such variables will have small standard
deviations, and thus are suppressed by the high-variance
metabolites in the unscaled analysis.
Up to now, we focused on the case where the weight
matrix is constant for each separate effect matrix. Yet, an
obvious, and for ASCA possibly fruitful, alternative strat-
egy is to use different weight matrices for each effect
matrix under consideration. We will denote this type of
scaling as effect scaling. In Eq. (4), effect scaling would
boil down to taking W aþabð Þ 6¼ WE. As a consequence, the
thus obtained solutions are no longer equivalent to OLS-
ASCA solutions of a scaled version of the input data matrix
(i.e., of any ~X ¼ XW). However, for each effect matrix
separately, the OLS solution of the effect matrix (.) scaled
with W(.) is equivalent to a WLS solution of the unscaled
effect matrix, with weight matrix W(.). This is so because
the scaling is still done per variable. This implies that—
analogously to the effect of using a single weight matrix—
the solutions based on unscaled and scaled data will gen-
erally differ more with increasing variability in the
diagonal elements of W(.).
2.3 Scaling in ASCA: choosing the weights
The key question now is how to select properweightmatrices
for ASCA. A weight matrix is proper when the effects of
interest are effectively displayed in the ASCA solution, de-
spite of nuisance effects (i.e., effects that are not of interest).
Thus, weights should be chosen such that the variability in
the data due to nuisance effects is diminished, while leaving
intact the variability due to the effect of interest.
In component analysis, it is rather common practice to use
per variable (l) the observed standard deviation (sdl) as the
scaling factor (i.e., wll = (sdl)
-1). However, in ASCA, dif-
ferent types of standard deviations can be computed, with the
differences pertaining to which conditions are considered
and which effect matrices are used. Hence, the question is
which of these standard deviations would most likely reflect
only nuisance effects, and thus would be useful for scaling.
Though the answer to this question partly depends on the
study and data at hand, a general guideline can be given. The
key is that the scaling factor should be free from the ex-
perimental effect of interest. A main effect of treatment, for
ð4Þ
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example, shows up in variance across treatment levels.Using
a scaling factor that includes the treatment variance thus
results in downweighting variables with large treatment ef-
fects. Those variablesmay hence remain unnoticed. Because
the effect of scaling depends on the mutual ratios in the
weights that are used for the scaling, this undesirable effect
can be expected to occur especially for variables for which
the treatment effect makes up a relatively large part of the
scaling factor. As we will explain, different effect matrices
(i.e., between and within effect matrices) may require dif-
ferent types of scaling.
Between effect In decomposing X aþabð Þ, one aims at iden-
tifying those variables for which the treatment effects and their
differential effects across time are largest. A suitable scaling
factorwould be free from those sources of variance.Wediscuss
three types of scaling factors, which all meet this requirement.
1. Overall residual standard deviation The matrix XE
(NK 9 L) contains the residuals, and expresses the varia-
tion between subjects within each condition (i.e., time
point and treatment combination). Using its columnwise sd
(i.e., sd per column of XE) results in a downweighting of
variables with relative large variation between subjects
within conditions. This makes sense because for those
variables the associated main and interaction effects will be
estimated with less precision.
When the residual variations would differ largely across
conditions for one or more variables, using the overall
residual sd s as the scaling factor seems to be problematic,
however. First, the size of an overall residual sd is
influenced heavily by (some) large within-condition vari-
ances for a given variable. This may yield a disproportional
downweighting of variables with small within-condition
variances across some conditions. This undesirable effect
would be precluded by taking a more robust measure, as
the median of all within-condition variances per variable.
Second, a treatment that induces large effects in means
across time, can very well be accompanied with increasing
variability across subjects (Jansen et al. 2012). Then, the
overall residual variance scaling would put less emphasis
on those variables with large effects in means—which are
to be identified. In this case, scaling with the overall
residual sd is to be discouraged, and a measure expressing
the amount of natural variation is needed.
2. Natural residual variation: pre-intervention/reference
group residual sd In case the experimental design includes
a pre-intervention phase or a reference group, the natural
variation within a condition can be estimated. When pre-
intervention data are available, one could use the residual sd
within all conditions using only the time point(s) before
treatment actually starts (i.e., sd per column of XE;pre, with
XE;pre the part of XE pertaining to the pre-intervention
phase). If one of the treatment groups could be considered a
reference group, pertaining to absence of treatment, or
treatment as usual, one could to use the residual sd in the
reference group (i.e., sd per column of XE;ref , with XE;ref the
part of XE pertaining to the reference group, denoted as
reference residual scaling for short). Indeed, for identifying
a differential treatment effect, variables with relatively large
variability in the reference group are of less interest than
variables with a small variability.
3. Reference group sd If there are variables with a sub-
stantial time effect (e.g., a trend) in the reference group,
one may express this in the measure of natural variation.
This can be done via the sd of the reference group scores on
all time points (i.e., sd per column of Xref, with Xref the
observed scores in the reference group), to be denoted as
reference group scaling for short. In this case one includes
the main effect across time in the reference group in the
scaling factor, implying that variables with a substantial
time effect (e.g., a trend) are downweighted. Obviously,
reference group scaling and reference residual scaling will
only yield different results if a main effect across time is
actually present in the reference group for at least one or
the variables and this main effect differs considerably
across variables.
Within effect Since analyzing the within effect aims at
identifying differential effects of treatments on individuals,
those effects should be excluded from the scaling factor.
Further, a scaling factor including any between effect (e.g.,
a main effect across time in the reference group) appears
strange, since the between effects themselves are of no
influence on the residuals to be analyzed. However, it does
make sense to correct for any differences in residual
variability between variables in a reference condition. This
suggests the use of—analogously to the between case—the
pre-intervention or reference group residual sd. If both a
pretest phase and reference condition are lacking in the
experimental design, there seems no other option than to
resort to no scaling.
The scaling factors based on residuals (i.e., of XE or a
submatrix thereof) requires the computation of XE. This is
easily done by computing the centered version of each data
matrix Xjk (j = 1,…,J; k = 1,…,K), containing the ob-
served scores for treatment j at time point k, and
positioning those matrices below each other.
3 Simulated data example
3.1 Simulated data
To illustrate the effects of suitable and less suitable scaling
variants in ASCA, we use a small simulated data set. The
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data were simulated such that it comprises various effects,
which can be identified with ASCA. The experimental
design pertains to J = 3 treatments, including a reference
condition (e.g., placebo), with per condition 20 individuals,
who are measured at K = 10 non-equidistant time points,
reflecting tk = 0.00001, …,34 h after intake, on L = 7
variables. Details on the simulation model and parameters
are provided in the SM. The simulated data are depicted in
Fig. 1. Regarding between effects, expressing the treat-
ments and their differential effects across time, there are
three types of patterns. First, variables 1–4 (v1–v4 for
short) have a very early treatment effect peak (i.e., at 1 h).
Of those, v3 and v4 have a small and large, respectively,
linear time trend, and v1 and v2 no trend. Second, v5 and
v6 have a medium to late treatment effect peak; v5 has a
linear trend, and v6 has no trend. Third, v7 shows no be-
tween effect. For all variables with a treatment effect (i.e.,
v1–v6), treatment 2 has larger effects than treatment 1,
while the intensity of the effect differs between variables.
Regarding within effects, expressing interindividual
differences across time and treatments, there are three
types. For v1–v3, the variance of the residuals is propor-
tional to the mean per time point and treatment condition.
This property is visible best in Fig. 1 for v3 up to 5 h, since
the associated means are higher than at later time points.
For v5 and v6, two subtypes of individuals can be distin-
guished in the variables, namely those with a medium peak
(around 9 h) and those with a late peak (around 18 h). For
v4 and v7, the residuals are independent, with v4 having
larger variances than v7.
3.2 Between effects: analysis and results
For the between effects (i.e., related to (a ? ab)—see
Eq. 3), we consider the effects of four scaling types. The
types (and between-VAF) are no scaling (11.7 %), refer-
ence residual scaling (45.6 %), reference group scaling
(47.8 %) and autoscaling (39.3 %), suggesting sufficient
between-variability in the data to consider the between-
components. The first three scaling types are suitable, but
they stress different data aspects, though. Autoscaling,
which involves as the scaling factor per variable the sd of
the raw scores on the variable across all treatments, time
points and individuals, is less suitable, since it includes
treatment and differential treatment effects.
For each of the four between solutions, the first com-
ponent is primarily related to v1 to v4, and the second to v5
and v6. Those two components cover the experimental
Fig. 1 Simulated data, of 20
individuals per treatment
condition, at 10 time points, on
7 variables
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effects present in those data. Because the effects of scaling
can already be illustrated with the first component, we only
discuss those results. Plots for the second component are
provided in the SM (Fig. 1).
Figure 2 depicts per scaling type, the scores on the first
component across time per condition (left), and the asso-
ciated loadings (right). As can be seen in the left part of
Fig. 2, the component scores show highly similar patterns
across time for each type of scaling. This implies that the
associated loadings can be mutually compared directly.
The loadings of v1–v4 show clear differences in the rela-
tive importance of the variables. The loadings of no scaling
express the relative effect sizes—which can be seen al-
ready in Fig. 1—with relative large sizes for v3 and v4,
medium for v1 and small for v2.
The loadings of reference residual scaling express the
effect sizes of treatment relative to the residual variance
within the reference condition. The loading for v1 is largest,
followed by v3, v4, and v2. As can be verified in Fig. 1, this
ordering of effects indeed reflect the balance between
(relative larger) treatment effects and (relative smaller)
residual variances. That is, v1 has a low peak, but very low
residual variance in the reference condition; v3 and v4 both
have a high, and about equal, peak, and relatively low, and
about equal reference residual variances. Finally, v2 has a
low peak, with relatively large residual variance.
The loadings of the reference group scaling express the
treatment effect sizes relative to the total variance within
the reference condition. When comparing this scaling type
to reference residual scaling, it is to be expected that v3–v5
will be downweighted, because v3–v5 have a trend across
time, and the other variables have no trend. The trend for
v3 being smaller than for v4 and v5, results in less
downweighting of v3. Comparing the obtained relative
loadings with those after reference residual scaling shows
indeed lower loadings for v3–v5, with the largest decrease
for v4 and v5, as expected.
The loadings of the autoscaling express the treatment
effect sizes relative to a contstant, namely the overall
variance of each variable. For v1–v4 this ratio is about
equal, as indicated by the associated loadings for v1–v4.
This implies that autoscaling fails to reflect the relative
sizes of the treatment effect.
3.3 Within effects: analysis and results
For the within effects (i.e., related to (E)—see Eq. 3), we
consider the effects of three scaling types. The types (and
Fig. 2 Simulated data: between
effect after four scaling types.
Left scores on the first
component across time for each
treatment condition, with the
VAF of the between effect
matrix; right the associated
loadings
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within-VAF) are no scaling (2.4 %), reference residual
scaling (11.6 %), and autoscaling (24.6 %). Only the first
two are suitable scaling types. Figure 3 depicts the scores
on the first within component across time per condition
(left) and the associated loadings (right) per scaling type.
As can be seen in Fig. 3, the pattern in scores for no scaling
and reference residual scaling expresses the interindividual
differences in treatment response across time. The plot
clearly shows two subtypes in responders which are present
for v5 and v6. The key difference is in the estimated
relative size. For v5, the double peaks, and thus the asso-
ciated individual deviations from the mean, are higher than
for v6. The loadings of no scaling express this absolute
difference. In contrast, the loadings of the reference resi-
dual scaling express the balance between (large) individual
deviations and (small) reference residual variance. This
balance apparently is about equal for v5 and v6. Au-
toscaling equalizes the total variance across variables.
Because v7, unlike v1–v6, has no between variance, its
within variance is massive in comparison to the remaining
variables. Therefore, v7 dominates the first within com-
ponent after autoscaling, showing the—uninteresting—in-
dependent residuals across time. The two subtypes in
responders are visible in the second within component after
autoscaling (not shown).
4 Empirical data example: a nutrikinetics study
4.1 Study design
To study the bioavailability of polyphenols, 20 male sub-
jects underwent a treatment with a tea extract, a wine ex-
tract or a placebo extract in a cross-over design. Blood
samples were collected just before (0 h) and at 1, 2, 6, 9,
12, 24 and 36 h after the intake. The chemical identities of
the set of (poly-)phenolics were known prior to the start of
the study (i.e., targeted analysis). Pure standards were used
for the identification and quantification (see Materials and
Methods in van Velzen et al. 2014). The resulting data set
consists of measurements of 11 metabolites. From those 11
metabolites, two are deleted from the data because there
are so many zeroes in the data that the variances of the
different groups could not be determined. We refer to v1–
v9 to indicate the metabolites; their names are listed in the
SM. There is large interindividual variation which is often
the case in nutritional studies. To illustrate the effects of
scaling in ASCA, the data are now subjected to different
types of scaling before the ASCA analysis, among which
scaling with a reference group (i.e., the placebo group).
Note that scaling using the pretest data (i.e., at 0 h) would
be possible as well, but adds little to the illustration, since
Fig. 3 Simulated data: within
effect after three scaling types.
Left scores on the first
component across time per
condition, with the VAF of the
within effect matrix; right the
associated loadings
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the residual variances at pretest are rather similar to the
residual variances in the placebo group.
Of the raw data (depicted in the SM, Fig. 2), the total
variances differ greatly across metabolites. The metabolite
v7 has by far the largest variance (s2 = 682.9), followed by
v3 (s2 = 160.5). The four lowest variance metabolites have
a maximum variance of only s2 = 2.6 (v1, v5, v6 and v8).
After reference residual scaling (depicted in the SM,
Fig. 3), the situation is drastically changed compared to the
unscaled data. In the reference group scaled data, v8 has
the largest variance (s2 = 169.5), followed by v2
(s2 = 73.7). The top two largest variance metabolites of
the raw data (v7 and v3) are at the 3rd and 6th position (with
s2 = 42.3 and 5.8, respectively) after reference residual
scaling. As we verified, but do not show, the reference
group scaled data closely resembles the data after reference
residual scaling due to lack of a time trend of the placebo
treatment for all variables involved.
With respect to the time profiles, v3, v4 and v7 show
high resemblances. In the time profile of these three
metabolites shortly after the start of the experiment the
concentration starts to rise, the most for tea, and the
maximum is reached after approximately 2 h after which
the decrease starts. Further, v8 and v9 have maximum
values at around 10 h, which is much later than the peaks
for v1–v7.
4.2 Between effects: analysis and results
Analogously to the analyses of the simulated data, we
consider the between effects (with between-VAF) after no
scaling (36.7 %), reference residual scaling (32.4 %), ref-
erence group scaling (32.4 %), and autoscaling (33.7 %).
Figure 4 depicts the scores on the first component across
time per condition (left) and the associated loadings (right).
In Fig. 4, the component scores of the no scaling case show
a fast response after the start of the experiment with a
maximum at 2 h, after which a decay starts. As can be seen
from the associated loadings, the first component in no
scaling is primarily determined by v7, and to a somewhat
lesser extent v3 and v4. Their profiles resemble the profile
of v7, albeit at a lower height. This result is in agreement
with the data.
Applying reference residual scaling and reference
group scaling yields very similar data and therefore also
the ASCA results closely resemble one another. As can be
seen in Fig. 4, v8 and to a lesser extent v9 are the im-
portant metabolites. Those two metabolites have their
maximum value around 10 h after which there is a de-
crease. This is in agreement with the data after reference
group scaling.
For the between effect, autoscaling and no scaling yield
similar results in that the same variables (v3, v4, v7)
Fig. 4 Empirical data: between
effect after four scaling types.
Left scores on the first
component across time per
condition, with the VAF of the
between effect matrix; right the
associated loadings
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become apparent as important. However, the associated
loadings indicate similar relative importance for those
variables, which obviously was not the case in the no
scaling solution.
For this dataset the scaling type has a large influence on
the first component of the between effect. That is, the first
between components after no scaling and autoscaling show
totally different aspects of the data when compared to the
first between component after reference condition based
scalings. This suggests that a single component is insuffi-
cient to adequately describe the data, and therefore it was
decided to have a look at the second component of the
between effect.
Figure 5 depicts the second between component after
the four scaling types. In this figure, it can be observed that
in the second component for the unscaled data the vari-
ables with the early peak still dominate. The signs in
loadings (positive for v7 and negative for v3 and v4),
combined with the component scores with a maximum at
2 h and a minimum at 6 h, reflect that v7 shows a much
faster decay than v3 and v4. The variance in those three
metabolites is so dominant that the other metabolites (i.e.,
those with a peak around 10 h, or with a larger effect for
wine than for tea) hardly play a role in the first two
components. With reference residual scaling and reference
group scaling, the second component expresses the early
peak effect, largest for tea and followed by wine, primarily
for v2 and v7. With autoscaling, also an early peak effect is
expressed, but now with the largest effect for wine, pri-
marily for v1, v2 and v5.
4.3 Within effects: analysis and results
We considered the within-effects after no scaling (within-
VAF 22.0 %), reference residual scaling (45.0 %) and
autoscaling (48.3 %). In Fig. 6, the scores on the first
component are plotted across time for each condition (left),
and the associated loadings (right) after no scaling, refer-
ence residual scaling and autoscaling. As can be seen in
this figure, the within effect after no scaling results in a
high importance of variable 7. This reflects the relatively
large within variance in the tea condition, combined with
the fact that this metabolite has by far the largest values in
the data.
Both after autoscaling and reference residual scaling, the
first component of the within effect describes the individual
differences for v8 and v9. In the raw data it appears that the
maxima for v8 and v9 differ between the different indi-
viduals. This phenomenon is picked up by autoscaling and
reference residual scaling.
Fig. 5 Empirical data: between
effect after four scaling types.
Left scores on the second
component across time per
condition, with the VAF of the
between effect matrix; right the
associated loadings
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5 Concluding remarks
ASCA is powerful for identifying sources of variance due
to experimental manipulations among large numbers of
variables. We showed the importance of proper scaling in
ASCA. Proper scaling uses scaling factors free from the
effect of interest, thus excludes effects induced by the
experimental manipulation. Therefore, autoscaling is to be
discouraged, as it covers between-treatment variances. For
designs involving a reference group, we advise considering
the reference group sd as a scaling factor. For within ef-
fects, the residual variance is appropriate, while for be-
tween effects, the total variance (i.e., including any trend)
could also be useful. Further, we advise to make and in-
terpret plots of the unscaled and scaled data per variable—
to gain insight into the effects of the scaling applied.
The reference group sd may be (close to) zero for par-
ticular variable(s), for example, because consistently small
values are obtained. This would yield undefined (or ex-
tremely large) scaled variable(s); as a work-around one
could exclude the variable(s) concerned, analyze unscaled
data, or use as the scaling factor the standard deviation plus
a threshold as in Tusher et al. (2001).
The issue of scaling is also highly relevant to other
advanced methods based on separating sources of variation
according to the experimental design. One can think of
classification methods, as support vector machines and
random forests (of which the large effects of scaling have
been recently illustrated (Gromski et al. 2014), and of
methods intimately related to ASCA (Smilde et al. 2012),
as Scaled-to-maximum, aligned, and reduced trajectories
(Keun et al. 2004).
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